fosinopril has been researched along with Essential Hypertension in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ashcheulova, T; Demydenko, G; Gerasimchuk, N; Kochubiei, O; Rezunenko, Y | 1 |
Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe | 1 |
2 other study(ies) available for fosinopril and Essential Hypertension
Article | Year |
---|---|
PATHOGENETIC ADVANCES OF FOSINOPRIL SODIUM WITH HYDROCHLOROTHIAZIDE IN OBESE HYPERTENSIVE PATIENTS.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Case-Control Studies; Dinoprost; Diuretics; Drug Therapy, Combination; Endothelium, Vascular; Essential Hypertension; Female; Fosinopril; Humans; Hydrochlorothiazide; Male; Middle Aged; Nitric Oxide Synthase Type II; Obesity; Overweight; Receptors, Tumor Necrosis Factor, Type I; Tumor Necrosis Factor-alpha | 2017 |
[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
Topics: Adenine; Anticholesteremic Agents; Azetidines; Carnitine; Drug Combinations; Endothelium, Vascular; Essential Hypertension; Ezetimibe; Fosinopril; Humans; Hypertension; Non-alcoholic Fatty Liver Disease; Obesity; Vascular Diseases | 2014 |